RESULTS OF OBSERVATIONAL PROGRAM ON USE OF INSULIN GLARGINE (LANTUS®) IN COMBINATION WITH ORAL HYPOGLYCEMIC AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN ROUTINE CLINICAL PRACTICE


Cite item

Full Text

Abstract

The article presents the results of observational program on the use of insulin glargine in clinical practice foe the treatment of patients with type 2 diabetes mellitus (DM2) inadequately controlled on monotherapy with metformin or sulfonylurea. The program included 2500 patients. Addition of insulin glargine to metformin/sulfonylurea monotherapy resulted in improvement of glycemic control in patients with DM2 (reduction of average glycated hemoglobin level by 2,1 %, and fasting plasma glucose - by 4,4 mg/dL. Hypoglycemic episodes within 3 months after initiation of insulin glargine therapy have been reported in 17 % of patients, most of them have experienced only 1-2 episodes. Body weight did not increase in these patients.

References

  1. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
  2. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
  3. Nathan D, Buse JB, Davidson MB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 2009;32(1):193-203.
  4. Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006;37:495-501.
  5. Fritsche A, Schweitzer MA, Häring H-U; 4001 study group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-59.
  6. Massi Benedetti MM, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-96.
  7. Pan C-Y, Sinnassamy P, Chung K-D, et al. LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract 2007;76:111-18.
  8. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-86.
  9. Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-36.
  10. Yki-Järvinen, Dressler A, Ziemen M; HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-36.
  11. Dixon S, Peters JR. Evaluating the 'real' cost-effectiveness of health technology: reconciling the public interest with patients' interests. Curr Med Res Opin 2007;23(Suppl. 1):S1-S6.
  12. Davies M, Storms F, Shutler S, et al, AT.LANTUS study group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-88.
  13. Monnier L, Lapinski H, Collette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1C. Diabetes Care 2003;26:881-85.
  14. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
  15. Skyler S, Bergenstal R, Bonow R, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials // Diabetes Care 2009;32(1):187-92.
  16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой. М., 2009. 104 c.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies